Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial.
Saved in:
| Title: | Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial. |
|---|---|
| Authors: | Verweij ME; Department of Radiation-Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands m.e.verweij-5@umcutrecht.nl.; Department of Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands., Tanaka MD; Department of Radiation-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kensen CM; Department of Radiation-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Heide UA; Department of Radiation-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Marijnen CAM; Department of Radiation-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Janssen T; Department of Radiation-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Vijlbrief T; Department of Radiation-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Grevenstein WMU; Department of Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands., Moons LMG; Department of Gastroenterology, University Medical Centre Utrecht, Utrecht, The Netherlands., Koopman M; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands., Lacle MM; Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands., Braat MNGJA; Department of Radiology, University Medical Centre Utrecht, Utrecht, The Netherlands., Chalabi M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Maas M; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Huibregtse IL; Department of Gastroenterology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Grotenhuis BA; Department of Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands., Fijneman R; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Consten E; Department of Surgery, Meander Medical Centre, Amersfoort, The Netherlands.; Department of Surgery, University Medical Centre Groningen, Groningen, The Netherlands., Pronk A; Department of Surgery, Diakonessenhuis Utrecht Zeist Doorn, Utrecht, The Netherlands., Smits AB; Department of Surgery, Sint Antonius Hospital, Nieuwegein, The Netherlands., Heikens JT; Department of Surgery, Hospital Rivierenland, Tiel, The Netherlands., Eijkelenkamp H; Department of Radiation-Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands., Elias SG; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands., Verkooijen HM; Department of Radiation-Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands., Schoenmakers MMC; Department of Radiation-Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands., Meijer GJ; Department of Radiation-Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands., Intven M; Department of Radiation-Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands., Peters FP; Department of Radiation-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. |
| Source: | BMJ open [BMJ Open] 2023 Jun 15; Vol. 13 (6), pp. e065010. Date of Electronic Publication: 2023 Jun 15. |
| Publication Type: | Clinical Trial Protocol; Journal Article |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
